Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models

Neurochemistry International

Volumn 52, Issue 3, 2008, Pages 376-383

  Chandra, J N Narendra Sharath ^a   Malviya, Manish ^a   Sadashiva, C T ^a   Subhash, M N ^b   Rangappa, Kanchugarakoppal S ^a  

^a UNIVERSITY OF MYSORE   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Alzheimer's; Arecoline thiazolidinones; Binding; M1 agonists

Indexed keywords

2 (4 DIMETHYLAMINO PHENYL) 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL)THIAZOLIDIN 4 ONE; 2 (4 HYDROXO PHENYL) 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL)THIAZOLIDIN 4 ONE; 2 (4 HYDROXY 3 METHOXY PHENYL) 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL)THIAZOLIDIN 4 ONE; 2 (4 METHOXY PHENYL) 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL)THIAZOLIDIN 4 ONE; 2 ETHYL 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL)THIAZOLIDIN 4 ONE; 2 ISOBUTYL 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL)THIAZOLIDIN 4 ONE; 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL) 2 (2 NITRO PHENYL)THIAZOLIDIN 4 ONE; 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL) 2 4 TOYLTHIAZOLIDIN 4 ONE; 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL) 2 NONYLTHIAZOLIDIN 4 ONE; 3 (1 METHYL 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL) 2 PHENYLTHIAZOLIDIN 4 ONE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADDITION REACTION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BRAIN CORTEX; BRAIN HOMOGENATE; CATALYST; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; LEARNING; MALE; MAZE TEST; MEMORY; METHYLATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RECEPTOR BINDING; SPATIAL MEMORY; STRUCTURE ACTIVITY RELATION; WORKING MEMORY;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; ARECOLINE; BINDING, COMPETITIVE; BRAIN; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; MALE; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MOLECULAR STRUCTURE; MUSCARINIC AGONISTS; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, MUSCARINIC M1; THIAZOLIDINES;

RATTUS NORVEGICUS; RODENTIA;

EID: 38049095525     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2007.07.006     Document Type: Article

References (18)

1. Bartus R.T., Dean III R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
2. Christie J.E., and Shering A. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br. J. Psychiatry 138 (1981) 46-50
3. 3H-spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. Eur. J. Pharmacol. 49 (1978) 201-202
4. Fisher A., Brandeis R., Karton I., Pittel Z., Gurwitz D., Haring R., Sapir M., Levy A., and Heldman E. (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′)quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 257 (1991) 392-403
5. Fisher A., Brandeis R., Pittel Z., Karton I., Sapir M., Dachir S., Levy A., and Heldman E. (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats. Neurosci. Lett. 31 (1989) 325-331
6. Hyttel J., Nielsen J.B., and Nowak G. The acute effect of sertindole on brain 5-HT2, D2 and alpha 1 receptors (ex vivo radioreceptor binding studies). J. Neural. Transm. Gen. Sect. 89 (1992) 61-69
7. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
8. Perry R.H. Recent advances in neuropathology. Br. Med. Bull. 42 (1986) 34-41
9. Potter L.T., and Ferrendelli C.A. Affinities of different cholinergic agonists for the high and low affinity states of hippocampal M1 muscarine receptors. J. Pharmacol. Exp. Ther. 248 (1989) 974-978
10. Sarter M., Bodewitz G., and Stephens D.N. Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology (Berl.) 94 (1988) 491-495
11. Sauerberg P., Jeppesen L., Olesen P.H., Rasmussen T., Swedberg M.D., Sheardown M.J., Fink-Jensen A., Thomsen C., Thøgersen H., Rimvall K., Ward J.S., Calligaro D.O., DeLapp N.W., Bymaster F.P., and Shannon H.E. Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity. J. Med. Chem. 41 (1998) 4378-4384
12. Saunders J., and Freedman S.B. The design of full agonists for the cortical muscarinic receptor. Trends Pharmacol. Sci. 10 Suppl. (1989) 70-75
13. Sharma A.C., and Kulkarni S.K. Evidence for GABA-BZ receptor modulation in short-term memory passive avoidance task in mice. Methods Find Exp. Clin. Pharmacol. 12 (1990) 175-180
14. Sharma A.C., and Kulkarni S.K. Effects of MK-801 and ketamine on short-term memory deficits in passive avoidance step-down task paradigm in mice. Methods Find Exp. Clin. Pharmacol. 13 (1991) 155-159
15. Showell G.A., Gibbons T.L., Kneen C.O., MacLeod A.M., Merchant K., Saunders J., Freedman S.B., Patel S., and Baker R. Tetrahydropyridyloxadiazoles: semirigid muscarinic ligands. J. Med. Chem. 34 (1991) 1086-1094
16. Sitaram N., Weingartner H., and Gillin J.C. Human serial learning: enhancement with arecoline and choline impairment with scopolamine. Science 201 (1978) 274-276
17. Tariot P.N., Cohen R.M., Welkowitz J.A., Sunderland T., Newhouse P.A., Murphy D.L., and Weingartner H. Multiple-dose arecoline infusions in Alzheimer's disease. Arch. Gen. Psychiatry 45 (1988) 901-905
18. Yamamura H.I., and Snyder S.H. Muscarinic cholinergic binding in rat brain. Proc. Natl. Acad. Sci. U.S.A. 71 (1974) 1725-1729